Germany’s BioNTech SE said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialise its cancer antibody drug candidate.

OncoC4 will get a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties.

The companies said they will co-develop the candidate, ONC-392, as a monotherapy or as a combination therapy in various cancer indications.

A late-stage trial for the drug has been planned for this year, the companies said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)